Immedica Pharma to acquire Marinus Pharmaceuticals for $151m.

Immedica Pharma, a global rare disease company, agreed to acquire Marinus Pharmaceuticals, a pharmaceutical company committed to improving the lives of patients with seizure disorders, for $151m. "The acquisition of Marinus represents a transformative step in Immedica’s journey to further strengthen our position as a leading rare disease company. By adding ZTALMY to our portfolio, we significantly strengthen our capabilities and expand our presence in the United States, marking a new chapter in our mission to deliver impactful therapies for underserved patient populations," Anders Edvell, Immedica CEO.